CoChat

KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background Observational studies of patients with primary colorectal cancer have identified KRAS mutation as a marker of poor prognosis. To examine more directly whether KRAS mutations are associated with accelerated metastatic progression, we evaluated KRAS mutation as well as Ki-67 expression in patients with colorectal liver metastases not treated with cetuximab.Methods KRAS mutation status was assessed in a series of resected or sampled colorectal liver metastases. In a subset of these tumors, Ki-67 antigen expression was assessed by immunohistochemical stains. Median follow-up after liver resection or biopsy was 2.3 years.Results KRAS mutation in the liver metastasis was detected in 27% of the 188 patients. High Ki-67 expression in the liver metastasis was identified in 62% of 124 patients analyzed. Both markers were associated with multiple liver metastases and shorter time interval to their detection. KRAS mutation and high Ki-67 expression were independent predictors of poor survival after colon resection (hazard ratio [HR] 1.9 [95% confidence interval (95% CI), 1.1-3.4], HR 2.6 [95% CI, 1.4-4.8], respectively). Tumors with high Ki-67 expression were less likely to be selected for liver resection, and KRAS mutation was independently associated with poor survival after liver resection (HR 2.4 [95% CI, 1.4-4.0]).Conclusions KRAS mutation is associated with more rapid and aggressive metastatic behavior of colorectal liver metastases. These data suggest an important role for KRAS activation in colorectal cancer progression and support continued efforts to develop KRAS pathway inhibitors for this disease.

Overview

Integrity signals

Registry

Crossref · 10.1245/s10434-009-0605-3

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 186

Metadata

Authors
Nash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Paty, Philip B.
Venue
Annals of Surgical Oncology
Published
2009-09-01
Volume
17
Issue
2
Pages
572-578
ISSN
  • 1068-9265 (ISSN-L)
  • 1534-4681
OpenAlex
W2052820539
Cited by
172
References
30
Citations by year
2026: 4 · 2025: 8 · 2024: 3 · 2023: 5 · 2022: 15 · 2021: 12 · 2020: 6 · 2019: 15 · 2018: 9 · 2017: 7 · 2016: 19 · 2015: 12 · 2014: 16 · 2013: 13 · 2012: 14
FWCI
4.66
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Annals of Surgical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P01CA065930, 2 P01 CA65930-05A2)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
KRAS mutation, colorectal liver metastases, metastatic progression, Ki-67 expression, prognostic factors, hepatectomy, survival after resection, multiple liver metastases, cetuximab, colorectal cancer progression
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Liver Neoplasms, Male, Middle Aged, Mutation, Prospective Studies, Proto-Oncogene Proteins, Colorectal Neoplasms, Survival Rate, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease Progression, ras Proteins, Ki-67 Antigen, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases. https://app.cochat.ai/papers/10.1245/s10434-009-0605-3
The paper
Nash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B. (2010). KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-009-0605-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.